News

Piercing the hype around Patrick Soon-Shiong's 'Bioshield' cancer treatment

Clinical 72/100How we got 72/100Source tierEstablished referenceTier ceiling72/100Independent sourcesnot recordedPublished score72/100Scored at the ceiling for a established reference source — it cannot go higher. The number is the source page’s own score, hard-capped at the tier ceiling; corroboration is recorded but cannot lift a score past that cap. Under 40 a claim goes to review instead of publication. Full methodology →
July 28, 2026↗ source

STAT columnist Adam Feuerstein analyzes new clinical data for ImmunityBio's cancer drug Anktiva, arguing that the results contradict founder Patrick Soon-Shiong's claims of survival benefits in advanced lung cancer patients. The article highlights the drug's modest commercial performance for bladder cancer and notes the recent approval of a superior competitor by Johnson & Johnson.

Related peptides

Interleukin-15Interleukin-1
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.